Janux Therapeutics JANX
NASDAQ JANX
$12.04 -0.73 (-5.72%)
At close: Nov 10, 2026 · 4:00 PM EST

Janux Therapeutics (JANX) Preferred Stock Liabilities (2020 - 2021)

Updated

Janux Therapeutics' Preferred Stock Liabilities came in at $77.35 million for Q1 2021, up 257.7% from the prior quarter.

Analysis

Janux Therapeutics (JANX) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

At the end of FY2020, Janux Therapeutics' Preferred Stock Liabilities was $21.62 million.

  • Business Quant data shows JANX's Preferred Stock Liabilities at $21.62 million (Q4 2020), $17.13 million (Q3 2020) and $17.13 million (Q2 2020) in the three quarters before Q1 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn -
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn -
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn -
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn -
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn -
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn -
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn -
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn -
10 Janux Therapeutics 771.59 Mn -3.07 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 77.35 Mn
Dec 31, 2020 21.62 Mn
Sep 30, 2020 17.13 Mn
Jun 30, 2020 17.13 Mn
API Access

Janux Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=JANX&period=max&api_key=YOUR_API_KEY